Christopher Enterprises Comfrey Marketing For Internal Use Barred
This article was originally published in The Tan Sheet
Executive Summary
Federal Trade Commission settlement provisions that restrict marketing of, and impose warning requirements on, Christopher Enterprises' comfrey-containing supplements will not apply if the products contain no pyrrolizidine alkaloids
You may also be interested in...
Comfrey
FDA "would not necessarily object" to comfrey supplements that have had pyrrolizidine alkaloids removed during processing, agency notes in recent letter to AHPA. "We would expect such a product to be completely free of the pyrrolizidine alkaloids and not simply...processed to reduce the quantity of [PAs] present," FDA says. Letter clarifies July 6 notice to eight trade groups urging marketers to recall comfrey-containing supplements due to evidence linking PAs to liver damage (1"The Tan Sheet" July 9, p. 10). However, if a principal substance is removed from a dietary ingredient, a 75-day premarket notification is required, FDA notes. AHPA is seeking data from its members on PA-free analytical methods...
Comfrey Presents "Serious Health Hazard," ONPLDS Tells Industry
Marketers of comfrey-containing dietary supplements should recall all such products or face direct enforcement action, FDA asserts in a July 6 letter sent to eight trade groups.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC